A Phase 2 interventional study of SYH2072 tablets and Placebo in Primary Aldosteronism, sponsored by InnovStone Therapeutics Limited. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by InnovStone Therapeutics Limited (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Hyperaldosteronism with a site in China — 41 open to participants now, 44 under way, 1 of them phase 3. Hyperaldosteronism · China.
Among the 77 studies in Hyperaldosteronism with a site in China, this one is the 21st largest by planned enrollment of the 35 interventional ones that give a count, is one of 8 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 35 of the 43 other live ones, and was the 77th registered.
201 studies on the registry are indexed under Hyperaldosteronism; 92 are open to participants now.
Browse Hyperaldosteronism studies →41 of the 77 studies in Hyperaldosteronism with a site in China are open now. Recruiting first, the newest first:
Third Military Medical University · Sites in China
Ages 18–70
Chongqing Medical University · Sites in China
Xinjiang Medical University · Sites in China
Ages 18–80
Xinjiang Medical University · Sites in China
Ages 40+
Shumin Yang · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 69 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 31 (45%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 3 · Phase 4 6
First in 2014; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 63 across 94 interventional studies indexed under Hyperaldosteronism.
Median enrollment 110 across the 35 interventional studies, 346 across the 42 observational. Of the 26 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under InnovStone Therapeutics Limited, one of the names counted as CSPC Pharmaceutical Group Limited. Under that name alone:
InnovStone Therapeutics Limited is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
CSPC Pharmaceutical Group Limited has 1 study filed under Hyperaldosteronism — fewer than ten, so there is no comparison to draw.
9 of the studies in Hyperaldosteronism with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07007793Phase 3AstraZenecaParent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. | 2027-07-27 |
| NCT07470983Shandong Suncadia Medicine Co., Ltd.A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism | 2026-11 |
| NCT05561361Second Affiliated Hospital of Nanchang UniversityThe Effect of SAAE on Vascular Endothelial Function in PA Patients | 2026-11-30 |
| NCT06941116Qifu LiSteroids-Based Screening for Primary Aldosteronism | 2026-12-30 |
| NCT06250699Zhe MengA Single Center Randomized Controlled Study on the Promotion of Rapid Recovery | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Hyperaldosteronism with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to explore the efficacy and safety of SYH2072 tablets in Chinese participants with primary aldosteronism (PA) .
Participants diagnosed with primary aldosteronism will be randomly assigned to the SYH2072 group or the placebo group for a double-blind treatment period. SYH2072 (or matching placebo) will be administered once daily, with the dose up-titrated during the treatment period based on clinical response and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SYH2072 Tablets
Drug: SYH2072 tablets · Drug: Placebo
Placebo
Drug: Placebo
SYH2072 tablets administered orally, once daily (QD)
Placebo administered orally, once daily (QD).
Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8
To evaluate the efficacy of SYH2072 tablets in improving blood pressure in trial participants with primary aldosteronism (PA) in China.
Time frame: week 8
Start is estimated for Nov 2026; primary completion for Feb 2028, 14 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SYH2072
InnovStone Therapeutics Limited →